前列腺癌根治后PSA失败不同临床情境下68Ga-PSMA-11 PET/CT预测列线图
本研究纳入703例根治性治疗后确认PSA失败的前列腺癌患者,按四种临床情境分层,评估68Ga-PSMA-11 PET/CT阳性率并构建预测列线图。总体阳性率为51.2%,各分层阳性率分别为40.3%、54%、60.5%和86.9%(p < 0.001)。基于ISUP分级、PSA、PSA倍增时间和临床情境的列线图 bootstrap校正准确度为82%,最佳截断值为40%。
要点
- 68Ga-PSMA-11 PET/CT总体阳性率为51.2%,不同临床情境阳性率差异显著(p < 0.001)。
- ISUP分级、PSA、PSA倍增时间和临床情境为阳性扫描的独立预测因素(均p ≤ 0.04)。
- 列线图最佳截断值为40%,bootstrap校正准确度82%,决策曲线分析显示临床净获益>10%。
核心结论
- 该新型列线图在预测68Ga-PSMA-11 PET/CT阳性扫描方面具有良好准确度,预测值≥40%为最具信息量的截断值,可用于指导患者咨询。
研究设计与样本
- 研究纳入703例根治性治疗后确认PSA失败的前列腺癌患者,按临床情境分为四组:首次生化复发(组1)、挽救治疗后生化复发(组2)、根治性前列腺切除术后生化持续(组3)、二线系统治疗前的晚期前列腺癌(组4)。
- 采用多变量逻辑回归分析确定阳性扫描预测因素,基于回归系数构建列线图,并使用200次bootstrap重采样进行内部验证。
- 采用受试者工作特征(ROC)分析确定列线图推导的最佳截断值,并实施决策曲线分析(DCA)量化临床获益。
主要发现
- 68Ga-PSMA-11 PET/CT总体阳性率为51.2%,组1为40.3%,组2为54%,组3为60.5%,组4为86.9%(p < 0.001)。
- 多变量分析显示ISUP分级、PSA、PSA倍增时间和临床情境均为阳性扫描的独立预测因素(均p ≤ 0.04)。
- 基于多变量模型协变量构建的列线图bootstrap校正准确度为82%,列线图推导的最佳截断值为40%。
- 决策曲线分析中,列线图显示临床净获益>10%。
关键数值与推荐
- 列线图预测68Ga-PSMA-11 PET/CT阳性的最佳截断值为40%。
- 列线图bootstrap校正准确度为82%。
- 决策曲线分析显示列线图临床净获益>10%。
临床怎么用
- 该列线图可用于预测根治性治疗后PSA失败患者68Ga-PSMA-11 PET/CT阳性概率,辅助筛选适合接受PSMA PET成像的患者。
- 预测值≥40%被视为最具信息量的截断值,可用于患者咨询。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to develop a clinical nomogram to predict gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography (68Ga-PSMA-11-PET/CT) positivity in different clinical settings of PSA failure. MATERIALS AND METHODS: Seven hundred three (n = 703) prostate cancer (PCa) patients with confirmed PSA failure after radical therapy were enrolled. Patients were stratified according to different clinical settings (first-time biochemical recurrence [BCR]: group 1; BCR after salvage therapy: group 2; biochemical persistence after radical prostatectomy [BCP]: group 3; advanced-stage PCa before second-line systemic therapies: group 4). First, we assessed 68Ga-PSMA-11-PET/CT positivity rate. Second, multivariable logistic regression analyses were used to determine predictors of positive scan. Third, regression-based coefficients were used to develop a nomogram predicting positive 68Ga-PSMA-11-PET/CT result and 200 bootstrap resamples were used for internal validation. Fourth, receiver operating characteristic (ROC) analysis was used to identify the most informative nomogram's derived cutoff. Decision curve analysis (DCA) was implemented to quantify nomogram's clinical benefit. RESULTS: 68Ga-PSMA-11-PET/CT overall positivity rate was 51.2%, while it was 40.3% in group 1, 54% in group 2, 60.5% in group 3, and 86.9% in group 4 (p < 0.001). At multivariable analyses, ISUP grade, PSA, PSA doubling time, and clinical setting were independent predictors of a positive scan (all p ≤ 0.04). A nomogram based on covariates included in the multivariate model demonstrated a bootstrap-corrected accuracy of 82%. The nomogram-derived best cutoff value was 40%. In DCA, the nomogram revealed clinical net benefit of > 10%. CONCLUSIONS: This novel nomogram proved its good accuracy in predicting a positive scan, with values ≥ 40% providing the most informative cutoff in counselling patients to 68Ga-PSMA-11-PET/CT. This tool might be important as a guide to clinicians in the best use of PSMA-based PET imaging.
引用
- Ceci F, Bianchi L, Borghesi M, et al. Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. Eur J Nucl Med Mol Imaging. 2019. PMID: 31492993. doi:10.1007/s00259-019-04505-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。